Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

361
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
361
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids01:24

CNS Stimulants: Cocaine, Amphetamines and Cannabinoids

319
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its...
319
Analgesia and Pain Management01:25

Analgesia and Pain Management

763
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
763
Opioid Analgesics: Morphine and Other Natural Cogeners01:20

Opioid Analgesics: Morphine and Other Natural Cogeners

342
Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
342
Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

399
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
399
Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

231
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
231

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tobacco and Nicotine Dependence Vulnerability as a Function of Dopaminergic Dysregulation: Proposing a Novel Strategy to Promote Neurotransmitter Homeostasis.

Current neuropharmacology·2026
Same author

Spectral EEG-guided adaptive neuromodulation for social anxiety disorder, performance-only subtype: a case report.

Frontiers in psychiatry·2026
Same author

Opioid-Induced Nodding-Not a Nice Nap.

Acta scientific neurology·2026
Same author

Corrigendum to "Selective upregulation of fatty acid-binding protein 5 within the basolateral amygdala blunts stress-induced reinstatement of cocaine-seeking behavior in mice" [Neurosci. Lett. 878 (2026) 138558].

Neuroscience letters·2026
Same author

Reward Deficiency Syndrome (RDS): A Common Neurogenetic Trait/State of All Addictions: Is this the new DSM?

British journal of healthcare and medical research·2026
Same author

Sustained Attention Instability as a Cognitive Biomarker in Chronic Spine Pain: A 90-second Visual Attention Test.

European journal of pain (London, England)·2026

Related Experiment Video

Updated: Aug 29, 2025

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies
05:25

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies

Published on: December 29, 2021

2.6K

Review: Cannabinoids as Medicinals.

Jag H Khalsa1,2,3, Gregory Bunt4, Kenneth Blum5,6,7,8,9,10

  • 1Division of Therapeutics and Medical Consequences, Medical Consequences of Drug Abuse and Infections Branch, National Institute on Drug Abuse, NIH, Special Volunteer, 16071 Industrial Drive, Gaithersburg, MD 20877 USA.

Current Addiction Reports
|September 12, 2022
PubMed
Summary

Cannabinoids like cannabidiol (CBD) show potential but lack sufficient clinical evidence for widespread medical use. More rigorous studies are needed to support their therapeutic value beyond specific epilepsy and multiple sclerosis treatments.

Keywords:
CBDCannabidiolCannabinoidsCannabisDelta-9-tetrahydrocannabinolSubstance-related disordersTHC

More Related Videos

Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice
07:51

Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice

Published on: August 1, 2025

150
Ultrasonic-Assisted Extraction of Cannabidiolic Acid from Cannabis Biomass
05:46

Ultrasonic-Assisted Extraction of Cannabidiolic Acid from Cannabis Biomass

Published on: May 27, 2022

6.2K

Related Experiment Videos

Last Updated: Aug 29, 2025

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies
05:25

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies

Published on: December 29, 2021

2.6K
Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice
07:51

Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice

Published on: August 1, 2025

150
Ultrasonic-Assisted Extraction of Cannabidiolic Acid from Cannabis Biomass
05:46

Ultrasonic-Assisted Extraction of Cannabidiolic Acid from Cannabis Biomass

Published on: May 27, 2022

6.2K

Area of Science:

  • Pharmacology
  • Neuroscience
  • Medical Cannabis Research

Background:

  • Cannabis-derived compounds, particularly cannabinoids, are subjects of extensive debate regarding their therapeutic applications.
  • Numerous jurisdictions are considering or have legalized cannabinoids, such as cannabidiol (CBD), for medical use without regulatory approval.
  • A critical review of existing evidence is necessary to ascertain the clinical validity of these uses.

Purpose of the Study:

  • To review published literature over the past 30 years on the medicinal use of cannabinoids.
  • To evaluate the sufficiency of clinical evidence from well-designed studies supporting the use of CBD and other cannabinoids as medicines.
  • To determine if current evidence meets regulatory standards for therapeutic claims.

Main Methods:

  • Systematic review of scientific papers.
  • Searches conducted in PubMed and Google Scholar databases.
  • Analysis focused on clinical studies and trials published within the last three decades.

Main Results:

  • Cannabidiol (CBD) and other cannabinoids are not yet substantiated for broad medical indications.
  • Exceptions include limited, approved uses of CBD for specific pediatric epilepsy syndromes and CBD/THC for multiple sclerosis spasticity.
  • Existing research suggests potential therapeutic benefits but lacks robust clinical validation.

Conclusions:

  • While cannabinoids show promise, they are not ready for formal medical indications across a wide range of conditions.
  • Further preclinical and clinical research adhering to regulatory guidelines is essential.
  • Formal recommendation of CBD and other cannabinoids as medicines requires more high-quality evidence.